The BDO M&A Pharma team advised Vitruvian Partners on their acquisition of Phlexglobal. The terms of the deal were not disclosed, but the transaction establishes Vitruvian as majority shareholder of Phlexglobal. The new ownership will enable Phlexglobal to expand the global footprint of its industry-leading service offering and PhlexEview4 technology platform, in order to build on the Company’s premier position in a fast-growing market.
Phlexglobal is a leading provider of Trial Master File (TMF) solutions for global clinical trials, and has been central to the maturation of the TMF across the industry through participation in the creation of the TMF Reference Model. With approximately 70 active clients including 26 of the top 50 pharmaceutical companies, Phlexglobal is recognized as the predominant global TMF specialist in the market.
Vitruvian is an independent private equity firm which specializes in growth middle-market investments. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries spanning information technology, life sciences & healthcare, media, and financial, business and consumer services
"BDO provided excellent support to Vitruvian by contributing in-depth sector expertise, helpful negotiation advice and valuable relationships. These elements underpinned our ability to execute the deal faster and with more conviction than any other bidder".
Philip Russmeyer, Partner, Vitruvian